Skip to main content

Omnicell, Inc. (OMCL) Stock Analysis

SellModerate Confidence

Healthcare · Health Information Services

Sell if holding. Engine flags exit at $42.90. Multiple concerning factors. Consider reducing position..

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an... Read more

$42.90+24.5% A.UpsideScore 5.4/10#9 of 13 Health Information Services
Stop $39.83Target $53.32(analyst − 13%)A.R:R 1.6:1
Analyst target$61.29+42.9%7 analysts
$53.32our TP
$42.90price
$61.29mean
$70

Sell if holding. Engine flags exit at $42.90. Multiple concerning factors. Consider reducing position.. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.

Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 91d clear, semi cycle peak clear). Suitability: aggressive.

Thesis

Rewards
Strong earnings beat streak (3/4)
Analyst upside: 25%
Recent Analyst detected in news
Risks
No bear case signals

Key Metrics

P/E (TTM)98.0
P/E (Fwd)20.0
Mkt Cap$2.0B
EV/EBITDA26.2
Profit Mgn1.7%
ROE1.6%
Rev Growth14.9%
Beta0.86
DividendNone
Rating analysts14

Quality Signals

Piotroski F8/9

Options Flow

P/C1.43bearish
IV66%elevated
Max Pain$20-53.4% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.6
Support Resistance
2.9
52w Position
5.6

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
3.1
Quality Rank
4.6
Value Rank
4.9
GatesMomentum 6.7>=5.5A.R:R 1.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.60EARNINGS PROXIMITY 91d clearSEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
74 · Overbought
20D MA 50D MA 200D MAGOLDEN CROSSSupport $32.74Resistance $46.89

Price Targets

$40
$53
A.Upside+24.3%
A.R:R1.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Analyst Consensus

Analysts14
Consensus4.1/5
Avg Target$61

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-07-30 (91d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OMCL stock a buy right now?

Sell if holding. Engine flags exit at $42.90. Multiple concerning factors. Consider reducing position.. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $39.83. Score 5.4/10, moderate confidence.

What is the OMCL stock price target?

Take-profit target: $53.32 (+24.5% upside). Prior stop was $39.83. Stop-loss: $39.83.

Is OMCL overvalued or undervalued?

Omnicell, Inc. trades at a P/E of 98.0 (forward 20.0). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about OMCL?

14 analysts cover OMCL with a consensus score of 4.1/5. Average price target: $61.

What does Omnicell, Inc. do?Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and...

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Related stocks: WAY (Waystar Holding Corp.) · PRVA (Privia Health Group, Inc.) · HQY (HealthEquity, Inc.) · HNGE (Hinge Health, Inc.) · MMED (MiniMed Group, Inc.)